Aytu Biopharma Inc Financials
Aytu Biopharma Inc (AYTU) reported $66.4M in revenue for fiscal year 2025, up 1.8% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Stable revenue is not yet covering operating costs, leaving cash needs increasingly dependent on financing and a more leveraged balance-sheet structure.
In FY2025, the net loss was-$13.6M while operating cash flow was only-$1.9M ; the much smaller cash shortfall signals that noncash charges and working-capital timing softened the earnings loss. Yet free cash flow remained negative, so that gap did not turn the business into a self-funding operation.
With revenue broadly flat, gross margin fell from
Cash increased from
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Aytu Biopharma Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Aytu Biopharma Inc scores -3.13, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($25.2M) relative to total liabilities ($105.2M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Aytu Biopharma Inc passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
Aytu Biopharma Inc reported a net loss of $13.6M while operations used $1.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Aytu Biopharma Inc reported an operating loss of $7.8M against $3.7M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Aytu Biopharma Inc generated $66.4M in revenue in fiscal year 2025. This represents an increase of 1.8% from the prior year.
Aytu Biopharma Inc's EBITDA was -$2.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 136.7% from the prior year.
Aytu Biopharma Inc reported -$13.6M in net income in fiscal year 2025. This represents an increase of 14.4% from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Aytu Biopharma Inc recorded an outflow of $2.2M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 26.1% from the prior year.
Aytu Biopharma Inc held $31.0M in cash against $10.9M in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Aytu Biopharma Inc's gross margin was 69.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 6.2 percentage points from the prior year.
Aytu Biopharma Inc's operating margin was -11.8% in fiscal year 2025, reflecting core business profitability. This is down 9.3 percentage points from the prior year.
Aytu Biopharma Inc's net profit margin was -20.4% in fiscal year 2025, showing the share of revenue converted to profit. This is up 3.9 percentage points from the prior year.
Aytu Biopharma Inc's ROE was -71.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 14.3 percentage points from the prior year.
Capital Allocation
Aytu Biopharma Inc invested $1.3M in research and development in fiscal year 2025. This represents a decrease of 52.1% from the prior year.
Aytu Biopharma Inc invested $228K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 30.7% from the prior year.
Not reported for fiscal year 2025.
AYTU Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $56.6M | $66.4M+1.8% | $65.2M-39.3% | $107.4M+11.1% | $96.7M+47.3% | $65.6M+137.5% | $27.6M+277.5% | $7.3M+100.0% | $3.7M+13.6% | $3.2M+25.7% | $2.6M+878.8% | $262K+344.2% | $59K+3267.4% | $2K0.0% | $2K | N/A |
| Cost of Revenue | $19.9M | $20.6M+27.4% | $16.1M-60.4% | $40.8M-8.2% | $44.4M+21.8% | $36.4M+339.9% | $8.3M+276.1% | $2.2M+7.4% | $2.1M+44.7% | $1.4M+48.1% | $957K+986.2% | $88K | N/A | N/A | N/A | N/A |
| Gross Profit | $36.7M | $45.8M-6.6% | $49.1M-26.4% | $66.6M+27.4% | $52.3M+79.1% | $29.2M+50.9% | $19.4M+278.1% | $5.1M+218.0% | $1.6M-10.8% | $1.8M+12.4% | $1.6M+824.4% | $174K | N/A | N/A | N/A | N/A |
| R&D Expenses | $216K | $1.3M-52.1% | $2.8M-32.4% | $4.1M-67.7% | $12.7M+125.2% | $5.6M+226.5% | $1.7M+192.3% | $589K+251.5% | $168K-82.5% | $960K-84.3% | $6.1M+90.3% | $3.2M-18.2% | $3.9M | N/A | N/A | N/A |
| SG&A Expenses | $18.7M | $17.4M-12.9% | $20.0M-30.3% | $28.6M-8.1% | $31.2M+22.2% | $25.5M-26.7% | $34.8M+84.3% | $18.9M+6.5% | $17.7M+1.7% | $17.4M+104.8% | $8.5M+114.0% | $4.0M+69.7% | $2.3M+7747.0% | $30K-10.9% | $34K-60.3% | $85K |
| Operating Income | -$15.2M | -$7.8M-392.0% | -$1.6M+90.7% | -$17.1M+84.5% | -$109.9M-86.7% | -$58.9M-178.6% | -$21.1M-25.4% | -$16.8M+14.5% | -$19.7M+2.1% | -$20.1M+7.3% | -$21.7M-184.4% | -$7.6M-20.3% | -$6.3M | N/A | -$56K | N/A |
| Interest Expense | $2.2M | $3.7M-26.8% | $5.1M+1.9% | $5.0M+451.4% | $900K | N/A | $2.6M+386.7% | $536K-28.5% | $749K-70.4% | $2.5M-53.8% | $5.5M+4675.5% | $115K+352.4% | -$46K-1028.9% | $5K+47.8% | $3K+4.3% | $3K |
| Income Tax | $447K | $437K-79.6% | $2.1M | $0+100.0% | -$110K-142.5% | $259K | $0 | $0 | $0 | $0 | $0+100.0% | -$24K+97.1% | -$814K | N/A | N/A | N/A |
| Net Income | -$34.1M | -$13.6M+14.4% | -$15.8M+7.1% | -$17.1M+84.3% | -$108.8M-86.6% | -$58.3M-327.9% | -$13.6M+49.8% | -$27.1M-166.3% | -$10.2M+54.7% | -$22.5M+20.1% | -$28.2M-264.9% | -$7.7M-12413.0% | -$62K | N/A | -$60K | N/A |
| EPS (Diluted) | — | N/A | N/A | -$5.11 | -$74.01 | -$3.48 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
TTM is the trailing twelve months, Q4 FY2025 through Q3 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
AYTU Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $124.2M+5.2% | $118.1M-13.5% | $136.5M-0.8% | $137.6M-48.2% | $265.7M+73.3% | $153.3M+341.5% | $34.7M+64.9% | $21.1M+40.4% | $15.0M-38.4% | $24.3M+33.9% | $18.2M+51.3% | $12.0M+124174.5% | $10K-23.5% | $13K-44.6% | $23K |
| Current Assets | $79.2M+27.9% | $61.9M-15.0% | $72.8M+21.5% | $59.9M-43.1% | $105.2M+39.5% | $75.4M+388.7% | $15.4M+63.0% | $9.5M+212.7% | $3.0M-70.1% | $10.1M+25.8% | $8.0M+143.6% | $3.3M+177228.2% | $2K+901.1% | $186-95.6% | $4K |
| Cash & Equivalents | $31.0M+54.7% | $20.0M-13.0% | $23.0M+18.7% | $19.4M-61.0% | $49.6M+3.3% | $48.1M+335.4% | $11.0M+57.5% | $7.0M+774.0% | $802K-90.0% | $8.1M+9.5% | $7.4M+178.6% | $2.6M+141664.2% | $2K+1608.3% | $109-97.3% | $4K |
| Inventory | $11.4M-5.8% | $12.1M+1.2% | $12.0M+10.6% | $10.8M-33.6% | $16.3M+63.4% | $10.0M+594.3% | $1.4M+7.6% | $1.3M+2.0% | $1.3M+150.1% | $525K+1230.3% | $39K | N/A | N/A | N/A | N/A |
| Accounts Receivable | $31.2M+32.4% | $23.5M-18.7% | $28.9M+33.3% | $21.7M-22.9% | $28.2M+400.2% | $5.6M+223.6% | $1.7M+200.8% | $579K+9.6% | $528K+225.1% | $162K+3.4% | $157K | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | $0 | $0-100.0% | $65.8M+134.3% | $28.1M | $0 | N/A | $238K+7.9% | $221K+198.6% | $74K | N/A | N/A | N/A | N/A |
| Total Liabilities | $105.2M+16.4% | $90.4M-6.9% | $97.1M+4.1% | $93.3M-27.2% | $128.1M+119.8% | $58.3M+110.9% | $27.6M+261.9% | $7.6M-30.6% | $11.0M-22.9% | $14.3M+455.0% | $2.6M-61.4% | $6.6M+5414.8% | $121K+46.3% | $82K+41.0% | $58K |
| Current Liabilities | $63.1M+1.3% | $62.2M-9.8% | $69.0M+7.1% | $64.4M-41.1% | $109.4M+280.5% | $28.8M+435.4% | $5.4M+58.3% | $3.4M-6.0% | $3.6M-64.3% | $10.1M+583.8% | $1.5M-75.7% | $6.1M+4954.8% | $121K+46.3% | $82K+41.0% | $58K |
| Long-Term Debt | $10.9M+0.2% | $10.9M-26.1% | $14.7M+3.0% | $14.3M+7832.8% | $180K | $0 | $0 | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $19.0M-31.6% | $27.7M-29.6% | $39.4M-11.2% | $44.3M-67.8% | $137.6M+44.8% | $95.0M+1240.5% | $7.1M-47.2% | $13.4M+235.6% | $4.0M-60.3% | $10.1M-35.4% | $15.6M+190.8% | $5.4M+4943.6% | -$111K-59.0% | -$70K-95.9% | -$36K |
| Retained Earnings | -$333.5M-4.2% | -$320.0M-5.2% | -$304.1M-5.9% | -$287.1M-61.0% | -$178.3M-48.6% | -$120.0M-12.8% | -$106.4M-34.2% | -$79.3M-14.8% | -$69.1M-48.3% | -$46.6M-153.3% | -$18.4M-72.5% | -$10.7M-2131487.4% | -$5000.0% | -$5000.0% | -$500 |
AYTU Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $1.7M | -$1.9M-39.6% | -$1.4M+72.9% | -$5.1M+82.2% | -$28.8M-11.0% | -$26.0M+8.5% | -$28.4M-105.1% | -$13.8M+13.2% | -$15.9M-15.3% | -$13.8M-29.8% | -$10.7M-60.6% | -$6.6M-20.6% | -$5.5M-14492.5% | -$38K+0.4% | -$38K+41.6% | -$65K |
| Capital Expenditures | $34K | $228K-30.7% | $329K | N/A | $0-100.0% | $2.3M | $0-100.0% | $60K-19.9% | $75K-33.1% | $112K-55.9% | $253K | $0-100.0% | $9K | N/A | N/A | N/A |
| Free Cash Flow | $1.6M | -$2.2M-26.1% | -$1.7M | N/A | -$28.8M-1.8% | -$28.3M+0.2% | -$28.4M-104.3% | -$13.9M+13.3% | -$16.0M-14.9% | -$13.9M-27.8% | -$10.9M-64.5% | -$6.6M-20.4% | -$5.5M | N/A | N/A | N/A |
| Investing Cash Flow | -$3.0M | -$2.6M-678.1% | -$329K-181.2% | -$117K+96.4% | -$3.2M-16.8% | -$2.8M+50.8% | -$5.7M-432.6% | -$1.1M-119.3% | -$484K+86.3% | -$3.5M | N/A | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | $9.9M | $15.4M+1323.7% | -$1.3M-114.2% | $8.9M+479.8% | $1.5M-95.0% | $30.3M-57.3% | $71.1M+272.6% | $19.1M-15.8% | $22.7M+122.4% | $10.2M | N/A | N/A | N/A | $39K+16.2% | $34K-49.5% | $67K |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q4 FY2025 through Q3 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
AYTU Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 69.0%-6.2pp | 75.3%+13.2pp | 62.0%+8.0pp | 54.1%+9.6pp | 44.5%-25.5pp | 70.0%+0.1pp | 69.9%+25.9pp | 44.0%-12.0pp | 56.0%-6.6pp | 62.6%-3.7pp | 66.3% | N/A | N/A | N/A | N/A |
| Operating Margin | -11.8%-9.3pp | -2.4%+13.5pp | -15.9% | -113.7% | -89.7%-13.2pp | -76.5% | -230.1% | -538.2% | -624.7% | -847.0% | -2915.5% | -10770.3% | N/A | -3220.3% | N/A |
| Net Margin | -20.4%+3.9pp | -24.3%-8.4pp | -15.9% | -112.5% | -88.8%-39.5pp | -49.3% | -370.6% | -278.4% | -698.7% | -1099.7% | -2950.3% | -104.7% | N/A | -3410.0% | N/A |
| Return on Equity | -71.5%-14.3pp | -57.2%-13.9pp | -43.3%+202.2pp | -245.5%-203.1pp | -42.4%-28.0pp | -14.3%+368.5pp | -382.8%-306.9pp | -75.9%+486.8pp | -562.7%-283.3pp | -279.4%-230.0pp | -49.5%-48.3pp | -1.1% | N/A | N/A | N/A |
| Return on Assets | -10.9%+2.5pp | -13.4%-0.9pp | -12.5%+66.5pp | -79.0%-57.1pp | -21.9%-13.1pp | -8.9%+69.3pp | -78.1%-29.8pp | -48.4%+101.7pp | -150.1%-34.3pp | -115.8%-73.3pp | -42.5%-42.0pp | -0.5% | N/A | -471.8% | N/A |
| Current Ratio | 1.26+0.3x | 0.99-0.1x | 1.06+0.1x | 0.930.0x | 0.96-1.7x | 2.62-0.3x | 2.87+0.1x | 2.79+2.0x | 0.84-0.2x | 1.00-4.4x | 5.44+4.9x | 0.54+0.5x | 0.020.0x | 0.00-0.1x | 0.07 |
| Debt-to-Equity | 0.57+0.2x | 0.390.0x | 0.37+0.1x | 0.32+0.3x | 0.000.0x | 0.000.0x | 0.000.0x | 0.00-2.7x | 2.75+1.3x | 1.41+1.2x | 0.16-1.1x | 1.24 | N/A | N/A | N/A |
| FCF Margin | -3.3%-0.6pp | -2.6% | N/A | -29.8%+13.3pp | -43.1% | -102.7% | -189.8% | -437.5% | -432.7% | -425.8% | -2534.3% | -9352.4% | N/A | N/A | N/A |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Aytu Biopharma Inc Ranks
Frequently Asked Questions
What is Aytu Biopharma Inc's annual revenue?
Aytu Biopharma Inc (AYTU) reported $66.4M in total revenue for fiscal year 2025. This represents a 1.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Aytu Biopharma Inc's revenue growing?
Aytu Biopharma Inc (AYTU) revenue grew by 1.8% year-over-year, from $65.2M to $66.4M in fiscal year 2025.
Is Aytu Biopharma Inc profitable?
No, Aytu Biopharma Inc (AYTU) reported a net income of -$13.6M in fiscal year 2025, with a net profit margin of -20.4%.
What is Aytu Biopharma Inc's EBITDA?
Aytu Biopharma Inc (AYTU) had EBITDA of -$2.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Aytu Biopharma Inc have?
As of fiscal year 2025, Aytu Biopharma Inc (AYTU) had $31.0M in cash and equivalents against $10.9M in long-term debt.
What is Aytu Biopharma Inc's gross margin?
Aytu Biopharma Inc (AYTU) had a gross margin of 69.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Aytu Biopharma Inc's operating margin?
Aytu Biopharma Inc (AYTU) had an operating margin of -11.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Aytu Biopharma Inc's net profit margin?
Aytu Biopharma Inc (AYTU) had a net profit margin of -20.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Aytu Biopharma Inc's return on equity (ROE)?
Aytu Biopharma Inc (AYTU) has a return on equity of -71.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Aytu Biopharma Inc's free cash flow?
Aytu Biopharma Inc (AYTU) recorded an outflow of $2.2M in free cash flow during fiscal year 2025. This represents a -26.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Aytu Biopharma Inc's operating cash flow?
Aytu Biopharma Inc (AYTU) recorded an outflow of $1.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Aytu Biopharma Inc's total assets?
Aytu Biopharma Inc (AYTU) had $124.2M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Aytu Biopharma Inc's capital expenditures?
Aytu Biopharma Inc (AYTU) invested $228K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Aytu Biopharma Inc spend on research and development?
Aytu Biopharma Inc (AYTU) invested $1.3M in research and development during fiscal year 2025.
What is Aytu Biopharma Inc's current ratio?
Aytu Biopharma Inc (AYTU) had a current ratio of 1.26 as of fiscal year 2025, which is considered adequate.
What is Aytu Biopharma Inc's debt-to-equity ratio?
Aytu Biopharma Inc (AYTU) had a debt-to-equity ratio of 0.57 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Aytu Biopharma Inc's return on assets (ROA)?
Aytu Biopharma Inc (AYTU) had a return on assets of -10.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Aytu Biopharma Inc's Altman Z-Score?
Aytu Biopharma Inc (AYTU) has an Altman Z-Score of -3.13, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Aytu Biopharma Inc's Piotroski F-Score?
Aytu Biopharma Inc (AYTU) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Aytu Biopharma Inc's earnings high quality?
Aytu Biopharma Inc (AYTU) reported a net loss of $13.6M while operations used $1.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Aytu Biopharma Inc cover its interest payments?
Aytu Biopharma Inc (AYTU) reported an operating loss of $7.8M against $3.7M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Aytu Biopharma Inc?
Aytu Biopharma Inc (AYTU) scores 46 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.